Here, we investigated the role of FGF signaling in resistance to CDK4/6 inhibitors or ET and the effects of tasurgratinib on drug resistance in preclinical ER+/HER2− breast cancer cell lines and patient-derived xenograft (PDX) models. Here, ESR1 is linked to breast cancer.